îæ€çŽ¢
îæ€çŽ¢
î
Inhibikase Therapeutics Inc
IKTîãŠã©ãããªã¹ãã«è¿œå
2.330USD
+0.160+7.37%
çµå€Â 07-23 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
307.64Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
詳现æ å ± Inhibikase Therapeutics Inc äŒæ¥å
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Companyâs multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Inhibikase Therapeutics Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãIKT
äŒç€ŸåInhibikase Therapeutics Inc
äžå Žæ¥Dec 23, 2020
æé«çµå¶è²¬ä»»è
ãCEOãIwicki (Mark T)
åŸæ¥å¡æ°15
蚌åžçš®é¡Ordinary Share
決ç®ææ«Dec 23
æ¬ç€Ÿæåšå°1000 N. West Street, Suite 1200
éœåžWILMINGTON
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·19801
é»è©±çªå·13022953800
ãŠã§ããµã€ãhttps://www.inhibikase.com/
äŒæ¥ã³ãŒãIKT
äžå Žæ¥Dec 23, 2020
æé«çµå¶è²¬ä»»è
ãCEOãIwicki (Mark T)
Inhibikase Therapeutics Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
--
-100.00%
Mr. David Canner, Ph.D.
Mr. David Canner, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
ãããã質å
Inhibikase Therapeutics Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îInhibikase Therapeutics Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ããDr. Christopher H. (Chris) Cabell, M.D.
Inhibikase Therapeutics IncïŒIKTïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2026Q1æç¹ã§ãInhibikase Therapeutics Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯152瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ103.21Mã§ãå
šäœã®78.17%ãå ããŠããŸãã2025Q4ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯43845693.00å¢å ããŠããŸãã